OnCo
ideasIdea

Non-endoscopic screening for Barrett's oesophagus and early adenocarcinoma

A swallowed sponge on a string can sample the oesophagus in a GP's office. Screen people with chronic reflux to catch adenocarcinoma at a curable stage.

Capsule sponge (Cytosponge-TFF3) detected ten times more Barrett's than usual care in the BEST3 trial (Lancet 2020); BEST4 (NIHR, 120,000 participants) tests whether screening and surveillance reduce mortality. Combining with methylation markers (EsoGuard) and AI histology could scale it.

Hypothesis
Offering capsule-sponge screening to adults on long-term acid suppression increases the proportion of oesophageal adenocarcinomas diagnosed at stage I and reduces oesophageal cancer mortality.
Rationale
Adenocarcinoma has a known precursor, a defined at-risk population, and curative endoscopic treatment for early disease; the missing piece is an accessible test.
What would test it
The BEST4 screening and surveillance arms (mortality and stage-shift endpoints) report in the late 2020s.
Maturity
being tested at scale

Connected

7top